Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vinblastine Sulfate,Cisplatin,2-hydroxybenzoyl Amino Octanoate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : SAKK
Deal Size : Undisclosed
Deal Type : Collaboration
Intensity Therapeutics, Sakk Ink Agreement for Phase 2 Trial in Early-Stage Cancer
Details : The collaboration aims to conduct a phase 2 trial evaluating the clinical and biological effects of intratumoral INT230-6 in early-stage triple-negative breast cancer.
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 13, 2024
Lead Product(s) : Vinblastine Sulfate,Cisplatin,2-hydroxybenzoyl Amino Octanoate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : SAKK
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : 2-hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate,Cisplatin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : The Benchmark Company
Deal Size : $19.5 million
Deal Type : Public Offering
Details : The company intends to use the net proceeds for the development of INT230-6, a formulation consisting of its proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplat...
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 30, 2023
Lead Product(s) : 2-hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : The Benchmark Company
Deal Size : $19.5 million
Deal Type : Public Offering
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : INT230-6 is designed for direct intratumoral injection, composed of two proven, potent anti-cancer agent, cisplatin and vinblastine, and penetration enhancer molecule that help disperse potent cytotoxic drugs throughout tumors for diffusion into cancer c...
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 18, 2022
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IMM60,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Portage Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Translational analysis of IMM60 confirms that PORT-2 activates iNKT cells, NK cells and dendritic cells, supporting the mechanism of action to stimulate both the adaptive and innate immune system.
Brand Name : IMM60
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 06, 2022
Lead Product(s) : IMM60,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Portage Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data show INT230-6 (Cisplatin), is designed for direct intratumoral injection is well tolerated and elicits both direct tumor killing and immune activating effects in a variety of solid tumors.
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 03, 2022
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : INT230-6
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : INT230-6, Intensity’s lead proprietary investigational product candidate, is designed for direct intratumoral injection was discovered using Intensity’s proprietary DfuseRx℠ technology platform.
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2021
Lead Product(s) : INT230-6
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data in the first poster show that INT230-6, monotherapy or in combination with pembrolizumab, is well tolerated and elicits both direct tumor killing and abscopal effects. The second presentation reports similar results of INT230-6 with or without ipili...
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 02, 2021
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Salcaprozate Sodium
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Ottawa Hospital
Deal Size : Undisclosed
Deal Type : Agreement
Details : The Ottawa Hospital and The Ontario Institute for Cancer Research (OICR) to conduct a Phase II Randomized, Window of Opportunity (WOO) trial evaluating clinical and biological effects of intratumoral INT230-6 vs. no treatment in early stage breast cancer...
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 24, 2021
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Salcaprozate Sodium
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Ottawa Hospital
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Local delivery of INT230-6 as monotherapy into tumors induced an immune response with increases of activated CD4+ and CD8+ T-cells in the tumor without any immune-related adverse events.
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 11, 2020
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The scPharmaceuticals management team will discuss the FUROSCIX® development plan. FUROSCIX® is an investigational, proprietary formulation of furosemide that is administered subcutaneously via a wearable on-body, drug delivery system, for outpatient s...
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 17, 2020
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?